Evidence map›Paper›PMID 40523937›Full record

ArticleNature cell biology2025

ZNF280A links DNA double-strand break repair to human 22q11.2 distal deletion syndrome.

Thomas L Clarke, Hyo Min Cho, Ilaria Ceppi, Boya Gao, Tribhuwan Yadav, Giorgia G Silveira, Ruben Boon, Barbara Martinez-Pastor, Nana Yaa A Amoh, Belen Machin and 17 more

Abstract read
In one paragraph

Article in Nature cell biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. [Mefloquine HCl promotes DNA repair and alleviates radiation-induced lung epithelial cell injury].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Thomas L ClarkeThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. tlclarke@bu.edu.ORCID http://orcid.org/0000-0003-2295-7412
Hyo Min ChoThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Ilaria CeppiInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0001-6496-8983
Boya GaoDepartment of Molecular Genetics and Microbiology, School of Medicine, Duke University, Durham, NC, USA.
Tribhuwan YadavThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Giorgia G SilveiraThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-1798-0191
Ruben BoonThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9355-674X
Barbara Martinez-PastorMolecular Oncology Program, Spanish National Cancer Research Center (CNIO), Madrid, Spain.ORCID http://orcid.org/0000-0003-0960-1737
Nana Yaa A AmohThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Belen MachinThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Tiziano BernasocchiThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7130-5317
Dua AshfaqThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Josefina MendezThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Zeeba KamaliyanDepartment of Pathology and Laboratory Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA.ORCID http://orcid.org/0000-0002-8331-881X
José Del Río PantojaThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Giuliana Sardi RoginesThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Blaine T CrowleyThe 22q and You Center, Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-3272-5458
Daniel E McGinnThe 22q and You Center, Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Victoria GiuntaThe 22q and You Center, Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Oanh TranThe 22q and You Center, Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Elaine H ZackaiThe 22q and You Center, Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Li LanDepartment of Molecular Genetics and Microbiology, School of Medicine, Duke University, Durham, NC, USA.
Lee ZouThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3094-1058
Beverly S EmanuelThe 22q and You Center, Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Donna M McDonald-McGinnThe 22q and You Center, Division of Human Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-4077-250X
Petr CejkaInstitute for Research in Biomedicine, Faculty of Biomedical Sciences, Università della Svizzera italiana, Bellinzona, Switzerland.ORCID http://orcid.org/0000-0002-9087-032X
Raul MostoslavskyThe Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA. rmostoslavsky@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-7740-5212

Funding

Identifying chromatin factors essential for DNA repair using a novel high-throughput screening methodologyR00ES034443 · NIEHS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Thomas L Clarke · 2024 to 2026
$670k
A high throughput assay to identify novel chromatin factors that regulate DNA repairR21ES027931 · NIEHS · MASSACHUSETTS GENERAL HOSPITAL · PI MOSTOSLAVSKY, RAUL · 2018 to 2019
$463k
NIEHS NIH HHS R00 ES034443U.S. Department of Health & Human Services | National Institutes of Health (NIH) R21ES027931
6 · The paper itself

Abstract

DNA double-strand breaks (DSB) are among the most deleterious forms of DNA damage and, if unresolved, result in DNA mutations and chromosomal aberrations that can cause disease, including cancer. Repair of DSBs by homologous recombination requires extensive nucleolytic digestion of DNA ends in a process known as DNA-end resection. In recent years, progress has been made in understanding how this process is initiated, but the later stages of this process-long-range DNA-end resection-are not well understood. Many questions remain in terms of how the DNA helicases and endonucleases that catalyse this process are regulated, a key step to avoiding spurious activity in the absence of breaks. The importance of DNA-end resection in human disease is highlighted by several human genetic syndromes that are caused by mutations or deficiencies in key proteins involved in this process. Here, using high-throughput microscopy coupled with a cDNA 'chromORFeome' library, we identified ZNF280A as an uncharacterized chromatin factor that is recruited to breaks and essential for DNA DSB repair. Lack of ZNF280A drives genomic instability and substantial sensitivity to DNA-damaging agents. Mechanistically, we demonstrate that ZNF280A promotes long-range DNA-end resection by facilitating the recruitment of the BLM-DNA2 helicase-nuclease complex to DNA DSB sites, enhancing efficiency of the enzymatic activity of this complex at DNA damage sites. ZNF280A is therefore essential for DNA-end resection and DNA repair by homologous recombination. Importantly, ZNF280A is hemizygously deleted in a human genetic condition, 22q11.2 distal deletion syndrome. Features of this condition include congenital heart disease, microcephaly, immune deficiency, developmental delay and cognitive deficits-features that are associated with other human syndromes caused by defects in genes involved in DNA repair. Remarkably, cells from individuals with a 22q11.2 distal deletion have defects in DNA-end resection and homologous recombination, resulting in increased incidence of genomic instability. These phenotypes are rescued by reintroduction of ZNF280A, providing evidence of defective DNA repair as a potential mechanistic explanation for several clinical features associated with this human condition.

Indexed as

Chromosomes, Human, Pair 22DNA Breaks, Double-StrandedDNA RepairTranscription FactorsChromosome DeletionGenomic InstabilityHomologous RecombinationHumansTranscription Factors

Identifiers

PMID40523937
PMCPMC12947238

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.